Results 211 to 220 of about 39,459 (267)
Evaluation of Transport Time on Stress Biomarkers in Pigs. [PDF]
Vet Med SciCurrie S +4 more
europepmc +1 more source
"Ewing's sarcoma of the duodenum: a rare gastrointestinal presentation": case report and review of literature. [PDF]
World J Surg OncolAgrawal S, Paul P.
europepmc +1 more source
Characterization of Cytokine Treatment on Human Pancreatic Islets by Top-Down Proteomics. [PDF]
ProteomicsIves AN +8 more
europepmc +1 more source
Primary Multifocal Neuroendocrine Tumor of the Breast: A Diagnostic Dilemma. [PDF]
CureusRatnaparkhi S +4 more
europepmc +1 more source
Bladder paraganglioma presenting with atypical abdominal pain: A diagnostic challenge. [PDF]
Urol Case RepLuo Y, Huang J, Liu H.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical and investigative medicine. Medecine clinique et experimentale, 1995
Chromogranin A (CgA) is the major member of the granin family of acidic secretory glycoproteins that are expressed in all endocrine and neuroendocrine cells. Granins have been proposed to play multiple roles in the secretory process. Intracellularly, granins play a role in targeting peptide hormones and neurotransmitters to granules of the regulated ...
G N, Hendy +3 more
openaire +3 more sources
Chromogranin A (CgA) is the major member of the granin family of acidic secretory glycoproteins that are expressed in all endocrine and neuroendocrine cells. Granins have been proposed to play multiple roles in the secretory process. Intracellularly, granins play a role in targeting peptide hormones and neurotransmitters to granules of the regulated ...
G N, Hendy +3 more
openaire +3 more sources
Current Opinion in Endocrinology, Diabetes & Obesity, 2016
The review summarizes the utility and limitations of chromogranin A (CgA) as a circulating biomarker for neuroendocrine tumors (NETs).Blood CgA measurement has numerous clinical limitations including poor assay reproducibility, low sensitivity (meta-analysis: 73%, 95% confidence interval: 0.71-0.76), and a paucity of prospective validation studies.
Mark, Kidd, Lisa, Bodei, Irvin M, Modlin
openaire +2 more sources
The review summarizes the utility and limitations of chromogranin A (CgA) as a circulating biomarker for neuroendocrine tumors (NETs).Blood CgA measurement has numerous clinical limitations including poor assay reproducibility, low sensitivity (meta-analysis: 73%, 95% confidence interval: 0.71-0.76), and a paucity of prospective validation studies.
Mark, Kidd, Lisa, Bodei, Irvin M, Modlin
openaire +2 more sources
Measurements of chromogranin B can serve as a complement to chromogranin A
Regulatory Peptides, 2007CgA has been shown to be an excellent marker for neuroendocrine tumours. However, there are two major drawbacks with CgA measurements; elevated levels are common in patients with decreased renal function and in patients on treatment with proton pump inhibitors. These problems are not seen with CgB measurements.
Mats, Stridsberg +4 more
openaire +2 more sources
Chromogranin A and neuroendocrine tumors
Endocrinología y Nutrición (English Edition), 2013Chromogranin A (CgA) is the most abundant granin in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). As a tumor marker is moderately sensitive and nonspecific. Despite the limitations of testing methods, which require careful interpretation, especially in the case of gastrinomas, patients treated with somatostatin analogues, and poorly ...
José Ángel, Díaz Pérez +1 more
openaire +2 more sources
Endothelial Handling of Chromogranin A
2005The present study is the first to address the question of interaction between CGA and endothelial cells. It is evident that neither intact CGA nor N-terminal peptides activate endothelial cells by affecting the membrane potential. Nevertheless, bovine aorta endothelial cells (BAEC) bind and intemalise intact CGA in a temperature-dependent manner, and ...
MANDALA', Maurizio +3 more
openaire +3 more sources